Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function

Article ID	Journal	Published Year	Pages	File Type
6190330	Cancer Treatment and Research Communications	2016	7 Pages	PDF

Abstract

If an adjusted dose of amrubicin is used in patients with impaired hepatic function, the exposure of amrubicin and amrubicinol would be within the range of variation observed in patients with normal hepatic function.

Keywords

ALT ECoG AUC T-BIL Liver function test AST Aspartate aminotransferase Alanine aminotransferase Amrubicin dose adjustment eastern cooperative oncology group Pharmacokinetics area under the concentration–time curve Performance status total bilirubin

Related Topics

Health Sciences Medicine and Dentistry Oncology

Preview

Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function

Authors

Shinichiro Ryuge, Noriyuki Masuda, Nobuyuki Yamamoto, Toshiaki Takahashi, Haruyasu Murakami, Koji Takeda, Haruko Daga, Kimio Yonesaka, Hiroshi Tsukuda, Kazuhiko Nakagawa, Kaoru Tanaka, Katsuyuki Kiura, Nagio Takigawa, Toyoaki Hida, Takashi Seto,